ImageneBio (IMA) Common Equity (2020 - 2025)
ImageneBio (IMA) posted Common Equity of $133.1 million for Q4 2025, down 4.79% sequentially from $139.8 million in Q3 2025, and up 182.92% YoY from $47.1 million in Q4 2024.
ImageneBio (IMA) Common Equity (2020 - 2025) Analysis & Trends
ImageneBio has reported Common Equity for 6 years, with the latest figure at $133.1 million in Q4 2025.
- Quarterly Common Equity rose 182.92% year-over-year to $133.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $133.1 million (up 182.92% YoY) and the FY2025 annual result came in at $133.1 million, up 182.92% from the prior year.
- Common Equity slipped to $133.1 million in Q4 2025 per IMA's latest filing, from $139.8 million in the prior quarter.
- Over five years, Common Equity peaked at $227.6 million in Q1 2021 and troughed at -$180.4 million in Q2 2025.
- A 5-year average of $58.7 million and a median of $143.4 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2024: Common Equity soared 434.71% in 2021, then plunged 201.72% in 2024.
- Over 5 years, Common Equity stood at $207.9 million in 2021, then slipped by 29.3% to $147.0 million in 2022, then tumbled by 185.81% to -$126.1 million in 2023, then dropped by 27.32% to -$160.6 million in 2024, then soared by 182.92% to $133.1 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $133.1 million, $139.8 million, and -$180.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | ImageneBio | 48.60 Mn | -86.75 Mn | - | 133.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 133.14 Mn |
| Sep 30, 2025 | 139.83 Mn |
| Jun 30, 2025 | -180.35 Mn |
| Mar 31, 2025 | -169.60 Mn |
| Dec 31, 2024 | -160.57 Mn |
| Sep 30, 2024 | -152.75 Mn |
| Jun 30, 2024 | -146.58 Mn |
| Mar 31, 2024 | -137.35 Mn |
| Dec 31, 2023 | -126.11 Mn |
| Sep 30, 2023 | 155.34 Mn |
| Jun 30, 2023 | 156.70 Mn |
| Mar 31, 2023 | 135.02 Mn |
| Dec 31, 2022 | 146.97 Mn |
| Sep 30, 2022 | 158.79 Mn |
| Jun 30, 2022 | 174.37 Mn |
| Mar 31, 2022 | 192.96 Mn |
| Dec 31, 2021 | 207.88 Mn |
| Sep 30, 2021 | 203.26 Mn |
| Jun 30, 2021 | 216.26 Mn |
| Mar 31, 2021 | 227.64 Mn |